This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, R. Articles by Ladisch, S. Search for Related Content PubMed PubMed Citation Articles by Li, R. Articles by Ladisch, S.

Human Tumor Gangliosides Inhibit Murine Immune Responses in Vivo¹

Center for Cancer and Transplantation Biology, Children's Research Institute, and Departments of Pediatrics and Biochemistry/Molecular Biology, George Washington University School of Medicine, Washington, DC 20010

Gangliosides which are shed by tumor cells clearly inhibit cellular immune responses in vitro. However, the immunosuppressive activity of these molecules have been more difficult to ascertain in vivo. Here we have adapted a murine model to determine the effects of tumor gangliosides in an in vivo microenvironment, the lymph node draining the site of stimulation by allogeneic cells. In this model, allogeneic splenocytes (BALB/c) are s.c. injected into C3H mice. The cellular immune response in the draining popliteal lymph nodes 4 days later is evidenced as an increase in lymph node mass (2-fold), lymphocyte number (6-fold), and lymphocyte DNA synthesis (6-fold). Purified human neuroblastoma gangliosides (10 nmol) coinjected with the stimulating allogeneic cells significantly suppressed this in vivo immune response. The increase in the lymph node mass was reduced by 65% (0.66 versus 1.89 mg), the increase in lymphocyte number (4.0 x 10⁶ cells/node) was almost completely inhibited (1.1 x 10⁶ cells/node), and in vitro [³H]thymidine uptake by the lymphocytes recovered in vivo was reduced by 80%. In contrast to the inhibition by tumor gangliosides, liposomes of cholesterol:lecithin were not inhibitory. Thus, tumor gangliosides, specifically, modulate cellular immune responses in vivo, which may contribute to the observed enhancement of tumor formation by these molecules.

¹ This work was supported by Grants CA42361 and CA66010 from the National Cancer Institute and by a grant from the Phi Beta Psi Sorority.

² To whom correspondence and requests for reprints should be addressed, at Center for Cancer and Transplantation Biology, Children's Research Institute, 111 Michigan Avenue, NW, Washington, DC 20010.

Received 11/14/94. Accepted 12/ 1/94.

This article has been cited by other articles:

				A.-J. Dijkhuis, K. Klappe, W. Kamps, H. Sietsma, and J. W. Kok Gangliosides do not affect ABC transporter function in human neuroblastoma cells J. Lipid Res., June 1, 2006; 47(6): 1187 - 1195. [Abstract] [Full Text] [PDF]

				A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70 Cancer Res., June 15, 2005; 65(12): 5428 - 5438. [Abstract] [Full Text] [PDF]

				P. Rayman, A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al. Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses Clin. Cancer Res., September 15, 2004; 10(18): 6360S - 6366S. [Abstract] [Full Text] [PDF]

				M. V. Thornton, D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al. Degradation of NF-{kappa}B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas J. Immunol., March 15, 2004; 172(6): 3480 - 3490. [Abstract] [Full Text] [PDF]

				X. Zhang and F. L. Kiechle Glycosphingolipids in Health and Disease Ann. Clin. Lab. Sci., January 1, 2004; 34(1): 3 - 13. [Abstract] [Full Text] [PDF]

				D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells Cancer Res., April 1, 2003; 63(7): 1676 - 1683. [Abstract] [Full Text] [PDF]

				J. Peguet-Navarro, M. Sportouch, I. Popa, O. Berthier, D. Schmitt, and J. Portoukalian Gangliosides from Human Melanoma Tumors Impair Dendritic Cell Differentiation from Monocytes and Induce Their Apoptosis J. Immunol., April 1, 2003; 170(7): 3488 - 3494. [Abstract] [Full Text] [PDF]

				W. Deng, R. Li, M. Guerrera, Y. Liu, and S. Ladisch Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation Glycobiology, March 1, 2002; 12(3): 145 - 152. [Abstract] [Full Text] [PDF]

				A. Zakaryan, K. Karageuzyan, L. Hovsepyan, L. Karabashyan, and G. Zakaryan Quantitative analysis of phospholipids and gangliosides in bone marrow progenitors of lymphocytes, thymocytes and mature lymphocytes in tumor-bearing animals Int. Immunol., September 1, 2001; 13(9): 1141 - 1145. [Abstract] [Full Text] [PDF]

				G. V. Shurin, M. R. Shurin, S. Bykovskaia, J. Shogan, M. T. Lotze, and E. M. Barksdale Jr. Neuroblastoma-derived Gangliosides Inhibit Dendritic Cell Generation and Function Cancer Res., January 1, 2001; 61(1): 363 - 369. [Abstract] [Full Text]

				W. Deng, R. Li, and S. Ladisch Influence of Cellular Ganglioside Depletion on Tumor Formation J Natl Cancer Inst, June 7, 2000; 92(11): 912 - 917. [Abstract] [Full Text] [PDF]

				R. McKallip, R. Li, and S. Ladisch Tumor Gangliosides Inhibit the Tumor-Specific Immune Response J. Immunol., October 1, 1999; 163(7): 3718 - 3726. [Abstract] [Full Text] [PDF]